Literature DB >> 23661569

Zebularine inhibits the growth of A549 lung cancer cells via cell cycle arrest and apoptosis.

Bo Ra You1, Woo Hyun Park.   

Abstract

Zebularine (Zeb) is a DNA methyltransferase (DNMT) inhibitor to that has an anti-tumor effect. Here, we evaluated the anti-growth effect of Zeb on A549 lung cancer cells in relation to reactive oxygen species (ROS) levels. Zeb inhibited the growth of A549 cells with an IC50 of approximately 70 µM at 72 h. Cell cycle analysis indicated that Zeb induced an S phase arrest in A549 cells. Zeb also induced A549 cell death, which was accompanied by the loss of mitochondrial membrane potential (MMP; ΔΨm ), Bcl-2 decrease, Bax increase, p53 increase and activation of caspase-3 and -8. In contrast, Zeb mildly inhibited the growth of human pulmonary fibroblast (HPF) normal cells and lead to a G1 phase arrest. Zeb did not induce apoptosis in HPF cells. In relation to ROS level, Zeb increased ROS level in A549 cells and induced glutathione (GSH) depletion. The well-known antioxidant, N-acetyl cysteine (NAC) prevented the death of Zeb-treated A549 cells. Moreover, Zeb increased the level of thioredoxin reductase 1 (TrxR1) in A549 cells. While the overexpression of TrxR1 attenuated death and ROS level in Zeb-treated A549 cells, the downregulation of TrxR1 intensified death and ROS level in these cells. In conclusion, Zeb inhibited the growth of A549 lung cancer cells via cell cycle arrest and apoptosis. The inhibition was influenced by ROS and TrxR1 levels.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  A549; DNA methyltransferase; apoptosis; thioredoxin reductase; zebularine

Mesh:

Substances:

Year:  2013        PMID: 23661569     DOI: 10.1002/mc.22042

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Epigallocatechin-3-gallate enhances the therapeutic effects of leptomycin B on human lung cancer a549 cells.

Authors:  Meghan M Cromie; Weimin Gao
Journal:  Oxid Med Cell Longev       Date:  2015-04-01       Impact factor: 6.543

2.  Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.

Authors:  Ying Li; Min Zhu; Xiaoju Zhang; Dongjun Cheng; Xitao Ma
Journal:  Drug Des Devel Ther       Date:  2015-03-24       Impact factor: 4.162

Review 3.  Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug.

Authors:  Wen-Min Zhou; Bin Liu; Amin Shavandi; Lu Li; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

Review 4.  Epigenetic modulators as therapeutic targets in prostate cancer.

Authors:  Inês Graça; Eva Pereira-Silva; Rui Henrique; Graham Packham; Simon J Crabb; Carmen Jerónimo
Journal:  Clin Epigenetics       Date:  2016-09-15       Impact factor: 6.551

5.  DNMT3a promotes proliferation by activating the STAT3 signaling pathway and depressing apoptosis in pancreatic cancer.

Authors:  Wei Jing; Na Song; Yun-Peng Liu; Xiu-Juan Qu; Ya-Fei Qi; Ce Li; Ke-Zuo Hou; Xiao-Fang Che; Xiang-Hong Yang
Journal:  Cancer Manag Res       Date:  2019-07-10       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.